EHA 2023 | Ziftomenib: mechanism of action and promising results in patients with KMT2Ar or NPM1m AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the use of the menin inhibitor ziftomenib for patients with acute myeloid leukemia (AML). Dr Fathi provides an overview of the mechanism of action of ziftomenib and explains that patients with mutations in NPM1 and rearrangements in KMT2A have shown positive responses to this drug in ongoing clinical trials. Dr Fathi further describes an ongoing study evaluating the safety and efficacy of ziftomenib in patients with these genetic alterations, showing that the drug is mostly well tolerated and is very effective. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Abbvie, Servier, BMS, Astellas, Takeda, Genentech, Remix, Ipsen, Rigel, Menarini, Daiichi Sankyo, Orum, Amgen, Pfizer, Autolus, Forma, PureTech, and Mablytics. Clinical trial support from BMS, Servier, and Abbvie.
